ImmunoBrain Reports Positive Early-Stage Alzheimer's Immunotherapy Data

The clinical trial, conducted across 11 centers in the United Kingdom, Israel, and the Netherlands, focused on the safety and efficacy of an intermittent, short-acting checkpoint inhibitor. Researchers observed significant decreases in cerebrospinal fluid biomarkers linked to neuronal and synaptic damage, including neurogranin, total Tau, and pTau181, particularly among patients receiving the highest dosage. The study met its primary endpoint of safety and reported that the treatment was well tolerated.

This approach departs from traditional therapies that target specific pathological proteins within the brain. Instead, the mechanism relies on activating the peripheral immune system, a strategy pioneered over two decades by Professor Michal Schwartz at the Weizmann Institute of Science. By leveraging a short-lived antibody, the therapy aims to achieve target engagement while minimizing the risks associated with continuous immune exposure. ImmunoBrain is currently utilizing these findings to design the protocol for subsequent clinical development phases.